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We performed risk assessment for Crohn’s disease (CD) and ulcerative colitis (UC), the two common forms of inflammatory bowel dis-
ease (IBD), by using data from the International IBD Genetics Consortium’s Immunochip project. This data set contains ~17,000 CD
cases, ~13,000 UC cases, and ~22,000 controls from 15 European countries typed on the Immunochip. This custom chip provides a
more comprehensive catalog of the most promising candidate variants by picking up the remaining common variants and certain
rare variants that were missed in the first generation of GWAS. Given this unprecedented large sample size and wide variant spectrum,
we employed the most recent machine-learning techniques to build optimal predictive models. Our final predictive models achieved
areas under the curve (AUCs) of 0.86 and 0.83 for CD and UC, respectively, in an independent evaluation. To our knowledge, this is
the best prediction performance ever reported for CD and UC to date.Genome-wide association studies (GWAS) have been fruit-
ful in identifying disease susceptibility loci for Crohn’s
disease (CD [MIM 266600]) and ulcerative colitis (UC
[MIM 191390]), the two common forms of inflammatory
bowel disease (IBD [MIM 266600])1–3. However, it remains
unclear whether these advances can deliver sufficiently
accurate predictions to make targeted intervention realisti-
cally possible. There have been several early attempts to
harness GWAS for improving individual prediction of
complex disease risk. However, like many other complex
diseases, existing results for CD and UC risk prediction
are generally modest, if not negative.4–7
We argue that the discouraging risk prediction perfor-
mance so far may be attributed to three major factors:
insufficient sample size, incomprehensive catalog of vari-
ants, and the curse of high dimensionality in modeling
GWAS data. First of all, the previous sample sizes are
limited and may not be sufficient for the more challenging
IBD risk prediction. Sample sizes with a low number of
thousands were used in previous studies. By using a
similar sample size, we reported an AUC of 0.84 for
type 1 diabetes (T1D [MIM 222100]).8 The success of
T1D may be partially attributed to its high heritability
and strong dependence on the human leukocyte antigen
(HLA) genes. For the less heritable and less HLA-depen-
dent IBD,9 we may need more samples to achieve com-
parable performance. Second, most previous GWAS cover
only a proportion of common variants by using tag
SNPs, which are expected by linkage disequilibrium (LD)
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are less common or rare, can be interrogated well by exam-
ining common tag SNPs. Predictive power can, in turn, be
reduced as a result. Third, prediction for high-dimensional
data is computationally demanding and may suffer from
overfitting. Many existing approaches use a handful of
validated loci or simply prioritize and select predictors
by individual association significance. Neither of the two
strategies is optimal.
We performed risk assessment for IBD by using the
largest data set to date from the International IBD Genetics
Consortium’s Immunochip project. This data set provides
a total of 60,828 samples from 15 European countries,
including 20,076 CD cases, 15,307 UC cases, and 25,445
controls, typed by 11 different genotyping centers on the
Immunochip, a custom Illumina Infinium chip. This
custom chip is designed to perform both deep replication
of suggestive associations and fine mapping of established
GWAS significant loci. It provides a more comprehensive
catalog of the most promising candidate variants by pick-
ing up the remaining common variants and rare variants
that are missed in the first generation of GWAS. We
designed a two-step feature selection strategy for predic-
tion modeling.
After rigorous sample and SNP quality control (QC),
178,822 SNPs of 17,379 CD cases, 13,458 UC cases, and
22,442 health controls remained.3 We combined the CD
cases with the controls and randomly divided them into
three folds of equal size for preselection, training, and
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Figure 1. Ten-Fold Cross-Validation for Model Selection and Training
SNPs that survived fold 1 preselectionmay still contain noisy predictors. We employed L1-penalized logistic regression to further remove
irrelevant SNPs while fitting a predictivemodel using fold 2 data. The larger the penalty parameter lambda, themore SNPs were removed.
The numbers on the top of the plot are the corresponding numbers of SNPs survived under different values of lambda shown along the x
axis. We selected lambda by using 10-fold cross validation. Specifically, we calculated the average AUC for different values of lambda and
took the largest value yielding the most parsimonious model such that AUC is within 1 SE of the optimum (the two vertical dashed
lines). The optimal 10-fold cross-validated AUCs on fold 2 data were 0.864 and 0.830 for (A) CD and (B) UC, respectively.fold, we further required samples assigned to this fold may
not come from the previously published GWAS data sets.3
We conducted single SNP association tests by using the
first fold data set, based on which we filtered out SNPs
with p values > 104 and minor allele frequency
(MAF) < 0.01. As a result, 10,799 SNPs survived. The goal
of this preselection step was to reduce the large number
of predictors efficiently to a manageable range. Then we
applied penalized logistic regression (LR) with L1 pen-
alty10 to the survived SNPs of the second fold data set.
This L1 penalized approach carries out model selection
while fitting a predictive model. It tends to select only
one candidate among a group of SNPs with high pairwise
LD. Therefore, more SNPs may be filtered out for the final
predictive model. The number of SNPs entering into the
final model depended on the penalty parameter l, which
was selected by using 10-fold cross-validation (Figure 1).
Specifically, we calculated the average AUC for different
values of l and took the largest value of l (yielding the
most parsimonious model) such that AUC was within 1
SE of the optimum. The optimal 10-fold cross-validated
AUC over the second CD data set was 0.864. We ended
up with a 573-SNP CD predictive model. The same analysis
strategy was applied to the combined data set of the UC
cases and the controls. The control samples were shared
between the UC and CD data sets. After the preselection
step using the first fold UC data set, 6,968 SNPs survived.
The model selection and fitting using the second fold UCThe Americdata set achieved a 10-fold cross-validated AUC of 0.830
and resulted in a 366-SNP UC predictive model.
We tested the CD and UC predictive models on the third
fold data sets. They achieved AUC of 0.864 (95% CI ¼
[0.8573, 0.8692]) and 0.826 (95% CI ¼ [0.8164, 0.8315])
for CD and UC, respectively. To our knowledge, this is
the best prediction performance ever reported for CD
and UC. To decipher where the improved performance
came from, we evaluated several different forms of the
risk assessmentmodels.We first evaluated the contribution
by sample size.We used different percentages of the second
fold data set for training followed by testing on the third
fold data set. AUC results are shown in Figure 2A. We can
see that when sample size was small (a low number of
thousands) AUC was inferior (<0.8 for CD and <0.7 for
UC), consistent with previous studies. Because Figure 2A
suggests that the AUCmight not have peaked or plateaued
at a relative sample size of 100%, it was tempting to reckon
that even higher AUC might be achieved by using larger
sample sizes for the training data. Therefore we further
added samples from the testing fold to the training fold.
We observed very comparable plateaued AUC without sig-
nificant changes (see Table S1 available online). These
results suggest that we either reached the peaks for predic-
tion significance or that we required much greater sample
sizes to improve further. In addition, caution should be
used for batch effect when combining data from different
sources. Our batch effect check did not find evidence ofan Journal of Human Genetics 92, 1008–1012, June 6, 2013 1009
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Figure 2. Contribution of Sample Size and Predictors
For all experiments, we trained logistic regression models on fold 2 data and plotted AUCs of testing on fold 3 data.
(A) 10% sample sizes of fold 2 data were 1,327 and 1,197 for CD and UC, respectively.
(B) UC/CD: AUCs were achieved by using only the 30 CD-specific loci or the 23 UC-specific loci; UC/CD þ IBD: AUCs were achieved by
using the UC or CD loci plus the 110 IBD loci; UC þ CD þ IBD: AUCs were achieved by using all the 163 IBD loci; Affy500K: AUCs were
achieved by using the 1,201/724 CD/UC Immunochip SNPs that are also typed on the Affymetrix 500K chip; Illumina550K: AUCs were
achieved by using 1,728/1,142 CD/UC Immunochip SNPs that are also typed on the Illumina 550K chip; AffyGW6: AUCs were achieved
by using 1,933/1,204 CD/UC Immunochip SNPs that are also typed on Affymetrix Genome-Wide SNP Array 6.0 chip; full: AUCs were
achieved by using all Immunochip SNPs.such effects contributing to the high predictive ability
(Supplemental Information).
We next investigated the contribution by predictors. The
most recent IBD association study increases the number of
susceptibility loci to 163, including 23 UC-specific loci, 30
CD-specific loci, and 110 IBD loci.3 By using different com-
binations of these confirmed loci as predictors, we trained
LR on the second fold data set followed by testing on the
third fold data set. AUC results are shown in Figure 2B.
We note that these validated loci were selected by using
all data so the AUC results might be inflated. Even so,
the resulting performance was inferior (AUC < 0.75 for
CD and AUC < 0.7 for UC), confirming that using only
validated loci is not a good strategy for risk prediction. To
save cost, biotechnology companies design their popular
GWAS chips to cover only a proportion of common vari-
ants using tag SNPs. Out of the 10,799 preselected CD
SNPs, only 1,201, 1,728, and 1,933 are typed on the
popular Affymetrix 500K, Illumina550K, and Affymetrix
Genome-Wide SNP Array 6.0 chips, respectively. Similarly,
only 724, 1,142, and 1,204 out of the 6,968 preselected UC
SNPs are typed on the three chips, respectively. When
using only these SNPs for model selection, training, and
testing, we again obtained disappointing AUCs as shown
in Figure 2B. An examination of the final predictors
showed that more than 60% of the selected predictors
were not typed by current genotyping chips used for1010 The American Journal of Human Genetics 92, 1008–1012, JuneGWAS. The dense variant coverage of the Immunochip in-
creases the chance of including causal variants or impli-
cating them better with LD. We also noticed that many
final predictors were less common or rare (115 CD and
72 UC SNPs with MAF < 0.05). When filtering by using
MAF < 0.05 in fold 1, AUCs for fold 3 dropped to 0.825
and 0.780 for CD and UC, respectively. Together, these
results may partially explain the discouraging risk predic-
tion performance in previous studies that were not able
to utilize comprehensive catalog of variants.
Finally, we compared our approach with a previous sim-
ple log odds method.4 We estimated association signifi-
cance and odds ratio (OR) of each variant by using fold 1
and fold 2 data. We then took all variants with a
p value < 0.01 and pruned correlated ones slightly by
setting linkage disequilibrium (LD) threshold at r2 ¼ 0.8.
After pruning, 15,158 SNPs and 8,831 SNPs remained for
CD and UC, respectively. By using these SNPs, the simple
log odds method achieved AUCs of only 0.730 and 0.685
in predicting the testing data for CD and UC, respectively.
Even when varying significance thresholds were allowed,
the simple method achieved its best AUCs of only 0.767
and 0.705 for CD and UC, respectively. This analysis sub-
stantiated the improvement contributed by our more
appropriate modeling. These data sets are some of the
largest, if not the largest, ever used for SNP-based predic-
tion, with room to start exploring issues that have never6, 2013
been adequately addressed before. Therefore, we did some
preliminary exploration by conducting a cursory analysis
and comparing AUC from our linear additive models
with two other nonadditive models, Support Vector
Machines (SVM) with RBF kernels and gradient boosted
trees (GBT), allowing for modeling interactions. The SVM
demonstrated very comparable performance (AUC ¼
0.862 and 0.826 for CD and UC, respectively), whereas
GBT showed inferior performance (AUC ¼ 0.802 and
0.782 for CD and UC, respectively) (Table S3).
The logistic regression model gives a posterior pro-
bability of having the disease. By using a 0.5 cutoff, the
sensitivity of our model in predicting CD was 71% and
specificity was 83%, which were better than the 36% sensi-
tivity and 73% specificity based on the NOD2 (NOD2
[MIM 605956]) mutation.11 The clinical utility of this
performance depends on the disease prevalence at the
particular clinical setting. For example, assuming 2.5%
prevalence for relatives of CD patients12 implies a positive
predictive value of 10% and a negative predictive value
of 99%.
High dimensionality makes prediction very challenging.
A simple expression on how high dimensionality adversely
impacts classification performance has been obtained
recently.13 The difficulty of high-dimensional classifica-
tion is intrinsically caused by the many embedded noisy
features that do not contribute to the reduction of misclas-
sification rate. We often reasonably assume sparsity;
namely, that only a small proportion of the many candi-
date features are relevant, and apply the feature selection
in high-dimensional prediction. As a result, penalized
methods, because they achieve feature selection and classi-
fier construction simultaneously, have become very popu-
lar with the emergence of high-dimensional data in the
past decade.14 Representative penalties for variable selec-
tion include L1 (Lasso),10 SCAD,15 and elastic-net.16
Penalized methods have also been applied for genetic risk
prediction; for example, logistic regression with elastic-
net and L1 penalties,7 SVM with elastic-net and L1
penalties,17 and logistic regression with L1 and SCAD
penalties.18 See Abraham et al.17 for more examples and
references therein. It has been found that penalized
methods in general outperform unpenalized methods.18
Here we employ a two-step feature selection strategy,
namely, simple screening followed by L1 logistic regres-
sion. Theoretical justification for a similar strategy has
been obtained under linear regression setting with a
continuous response.19 The idea is to reduce dimension-
ality from high to a relatively large scale that is below the
sample size, by using fast and efficient independent
screening. The screening step aims to reduce dimension-
ality drastically, but at the same time it makes relevant fea-
tures survive. For example, we used p ¼ 104 as threshold
and believed that most, if not all, relevant features would
survive. Clearly this tradeoff had led to survival of quite a
few noisy features. We then further excluded them by
employing the extra lower dimensional model-selectionThe Americmethod with the L1 penalty. Such a two-step strategy
makes it more feasible to do model selection with ultra-
high dimensionality and speeds up variable selection dras-
tically. For example, we tried to combine fold 1 and fold 2
data and applied directly L1-regularized logistic regression
without screening. Our program needed over 100 GB RAM
and days for just loading the data. Comparable results were
obtained with CD AUC ¼ 0.869 and UC AUC ¼ 0.821.
The main reason we use L1 in our experiments for
model selection is that we employ computationally expen-
sive cross-validation to tune the penalty parameter. The L1
penalty has only one parameter to be tuned, while it has
two for SCAD and elastic-net. Given the size of the data,
it is prohibitively costly at present, if feasible at all, to
tune thoroughly over two or more parameters. There are
two reasons that we use simple linear models: their
much affordable computational cost and decent perfor-
mance for high-dimensional data. It is found that when
feature size (p) is much larger than sample size (n), linear
classifiers may give comparable or even better perfor-
mances than nonlinear ones in many applications,
although nonlinear methods are known to be more
flexible.20 There is some theoretical justification that
linear classifiers are natural choices to discriminate two
classes when p [ n.21 From a genetics point of view,
when many SNPs are typed, nonadditive effects may
have been interrogated well by individual markers that
can be characterized by using just linear models. Here,
we obtain very comparable performance when using
SVM with nonlinear RBF kernel. It is noted that because
of computational scope, we simply use default parameters
for SVM. We don’t exclude the possibility that both SVM
and GBT may be further improved with careful and
thorough parameter tuning.
In conclusion, our results for IBD lend support to an
optimistic view that genotype-based genetic risk predic-
tion may be feasible given sufficient sample size, compre-
hensive variant coverage, and proper modeling. With the
recent advance for large-scale high-dimensional modeling
in machine learning, new approaches warrant future study
for improving genetic risk prediction further.Supplemental Data
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